



**Grant Number:** 5U01CA033193-27

**Principal Investigator(s):**

Vincent J Cogliano, PHD

**Project Title:** Evaluation of Carcinogenic Risks to Humans

Peter Boyle  
DIRECTOR, DIV OF ADMIN & FINANCE  
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER  
150, COURS ALBERT THOMAS  
69372 LYON CEDEX 08  
LYON CEDEX,  
FRANCE

**Award e-mailed to:** daf@iarc.fr

**Budget Period:** 09/01/2008 – 08/31/2009

**Project Period:** 09/01/1985 – 08/31/2010

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$778,142 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to INTERNATIONAL AGENCY FOR RES ON CANCER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 & 6306 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release or other document that cites results from NIH grant-supported research must include an acknowledgment of NIH grant support and disclaimer such as "The project described was supported by Award Number U01CA033193 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health."

Award recipients are required to comply with the NIH Public Access Policy. This includes submission to PubMed Central (PMC), upon acceptance for publication, an electronic version of a final peer-reviewed, manuscript resulting from research supported in whole or in part, with direct costs from National Institutes of Health. The author's final peer-reviewed manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process. For additional information, please visit <http://publicaccess.nih.gov/>.

Award recipients must promote objectivity in research by establishing standards to ensure that the design, conduct and reporting of research funded under NIH-funded awards are not biased by a conflicting financial interest of an Investigator. Investigator is defined as the Principal Investigator and any other person who is responsible for the design, conduct, or reporting of NIH-funded research or proposed research, including the Investigator's spouse and dependent children. Awardees must have a written administrative process to identify and manage financial conflict of interest and must inform Investigators of the conflict of interest policy and of the Investigators' responsibilities. Prior to expenditure of these awarded funds, the Awardee must report to the NIH Awarding Component the existence of a conflicting interest and within 60 days of any new conflicting interests identified after the initial report. Awardees must comply with these and all other aspects of 42 CFR Part 50, Subpart F. These requirements also apply to subgrantees, contractors, or collaborators engaged by the Awardee under this award. The NIH website <http://grants.nih.gov/grants/policy/coi/index.htm> provides additional information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Galen Gregor  
Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows

---

**SECTION I – AWARD DATA – 5U01CA033193-27****Award Calculation (U.S. Dollars)**

Salaries and Wages	\$391,890
Fringe Benefits	\$130,663
Personnel Costs (Subtotal)	\$522,553
Consultant Services	\$26,033
Travel Costs	\$2,108
Other Costs	\$148,248

Federal Direct Costs	\$698,942
Federal F&A Costs	\$90,863
Approved Budget	\$789,805
Federal Share	\$789,805
Less Unobligated Balance	\$11,663
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$778,142</b>

**AMOUNT OF THIS ACTION (FEDERAL SHARE) \$778,142**

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
27	\$778,142	\$778,142
28	(b)(5)	

Recomm  
progress of the project

**Fiscal Information:**

CFDA Number: 93.393  
EIN: 1900210016A1  
Document Number: UCA033193F  
Fiscal Year: 2008

IC	CAN	2008	2009
CA	8423126	\$778,142	(b)(5)

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

PCC: 9QCG3126 / OC: 414P / Processed: GREGORG 08/07/2008

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 5U01CA033193-27**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – TERMS AND CONDITIONS – 5U01CA033193-27**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at 'http://grants.nih.gov/grants/policy/awardconditions.htm' for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

**Treatment of Program Income:**  
Additional Costs

---

**SECTION IV – CA Special Terms and Conditions – 5U01CA033193-27**

**INFORMATION** This award is issued as a Cooperative Agreement, a financial assistance mechanism which requires cooperation between the awardee and the National Cancer Institute (NCI). The following Terms of Cooperation include the Programmatic Responsibilities of the Grantees, the Nature of Assistance by NCI Staff, Collaborative Responsibilities, and Arbitration Procedures (Attachment 1).

These special Terms and Conditions of Award are in addition to and not in lieu of otherwise applicable OMB administrative guidelines, Federal Regulations, including HHS Grant Administration Regulations at 42 CFR Part 52, 45 CFR Parts 74 and 92, and other HHS, PHS, and NIH Grant Administration policy statements.

The following administrative terms also apply:

**RESTRICTION** This supplemental award provides \$47,607 (\$42,130 direct costs and \$5,477 associated facilities and administrative costs) to replace the support for the publication of IARC Monographs that was lost with the discontinuance of the support contract to TRI, as requested in the awardee's letter dated May 31, 2007. These funds are restricted and may not be expended for any other purpose without the written prior approval of the National Cancer Institute. Funds awarded are available for carryover for awards given carryover authority as reflected in section III of this award notice. However, the funds remain restricted for the purpose for which the supplement is awarded.

**INFORMATION:** This non-competing award reflects an adjustment of the amount recommended on the previous Notice of Grant Award, per National Cancer Institute's implementation of the NIH Fiscal Year 2008 funding policy (NIH Guide for Grants and Contracts Notice OD-08-036 <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-036.html>). Future year recommended levels also have been adjusted consistent with the referenced Notice.

Based upon NCI's acceptance of the direct costs budgets submitted for this budget period, funds included in this award for Facilities and Administrative costs have been adjusted accordingly.

**INFORMATION** This award utilizes as an offset the unobligated balance from the -25 year financial status report.

**INFORMATION** In a continuing effort to provide exceptional customer service, the NCI Grants Administration Branch has set up a Feedback address on its web site (<http://www.nci.nih.gov/admin/gab/index.htm>). General concerns and issues related to NCI grants policies, procedures, and practices can be sent to the Customer Liaison using this feature. Specific questions or concerns related to this grant should be addressed to the Grants Management Specialist listed in the Terms of Award.

**STAFF CONTACTS**

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Program Official:** Alan P. Poland  
**Email:** polanda@mail.nih.gov **Phone:** (301) 496-1625 **Fax:** (301) 496-1040

**SPREADSHEET SUMMARY**  
**GRANT NUMBER:** 5U01CA033193-27

**INSTITUTION:** INTERNATIONAL AGENCY FOR RES ON CANCER

<b>Budget</b>	<b>Year 27</b>	<b>Year 28</b>
Salaries and Wages	\$391,890	
Fringe Benefits	\$130,663	
Personnel Costs (Subtotal)	\$522,553	
Consultant Services	\$26,033	
Travel Costs	\$2,108	
Other Costs	\$148,248	
TOTAL FEDERAL DC	\$698,942	(b)(5)
TOTAL FEDERAL F&A	\$90,863	
TOTAL COST	\$778,142	

**Progress Report Scanning Cover Sheet**

**5U01CA033193-27**

PI Name: **COGLIANO, VINCENT**  
Org: **INTERNATIONAL AGENCY FOR RES ON  
CANCER**  
Start Date: **09/01/2008**  
Snap: **N/A (NEEDS TO BE BOOKMARKED)**  
AppI ID: **7496609**  
Rec'd  
Date: **07/09/2008**

Department of Health and Human Services Public Health Services	Review Group	Type <b>5</b>	Activity <b>U01</b>	Grant Number <b>3U01CA033193-25W1 27</b>
<b>Grant Progress Report</b>				
Total Project Period				
From: 09/01/1985			Through: 08/31/2010	
Requested Budget Period				
From: 09/01/2008			Through: 08/31/2009	


1. TITLE OF PROJECT <b>Evaluation of Carcinogenic Risks to Humans</b>	
2a. PRINCIPAL INVESTIGATOR OR PROGRAM DIRECTOR (Name and address, street, city, state, zip code) <b>Vincent James Cogliano Carcinogen Identification &amp; Evaluation Group International Agency for Research on Cancer 150, Cours Albert Thomas 69372 Lyon cedex 08, France</b>	3. APPLICANT ORGANIZATION (Name and address, street, city, state, zip code) <b>International Agency for Research on Cancer 150, Cours Albert Thomas 69372 Lyon cedex 08 France</b>  <b>JUL 09 2008</b>
2b. E-MAIL ADDRESS <b>cie@iarc.fr</b>	4. ENTITY IDENTIFICATION NUMBER <b>1900210016A1</b>
2c. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT <b>Carcinogen Identification &amp; Evaluation Group</b>	5. TITLE AND ADDRESS OF ADMINISTRATIVE OFFICIAL <b>Director, Division of Administration &amp; Finance International Agency for Research on Cancer 150, Cours Albert Thomas 69372 Lyon cedex 08 France</b>  E-MAIL: <b>daf@iarc.fr</b>
2d. MAJOR SUBDIVISION <b>Molecular Carcinogenesis Cluster</b>	

6. HUMAN SUBJECTS		7. VERTEBRATE ANIMALS	
<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	6a. Research Exempt <input type="checkbox"/> No <input type="checkbox"/> Yes	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	7a. If "Yes," IACUC approval Date
6b. Human Subjects Assurance No.		7b. Animal Welfare Assurance No.	
If Exempt ("Yes" in 6a): Exemption No.		6c. NIH-Defined Phase III Clinical Trial <input type="checkbox"/> No <input type="checkbox"/> Yes	
If Not Exempt ("No" in 6a): IRB approval date		<input type="checkbox"/> Full IRB <b>or</b> <input type="checkbox"/> Expedited Review	

8. COSTS REQUESTED FOR NEXT BUDGET PERIOD		9. INVENTIONS AND PATENTS	
8a. DIRECT \$712,782	8b. TOTAL \$805,444	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes If "Yes,"	<input type="checkbox"/> Previously Reported <input type="checkbox"/> Not Previously Reported

10. PERFORMANCE SITE(S) ( <i>Organizations and addresses</i> ) <b>International Agency for Research on Cancer 150, Cours Albert Thomas 69372 Lyon cedex 08 France</b>	11a. PRINCIPAL INVESTIGATOR OR PROGRAM DIRECTOR ( <i>Item 2a</i> )	TEL 33-4-72.73.84.76 FAX 33-4-72.73.83.19
	11b. ADMINISTRATIVE OFFICIAL NAME ( <i>Item 5</i> ) <b>Michael Johnson</b>	TEL 33-4-72.73.84.67 FAX 33-4-72.73.85.64
	11c. NAME AND TITLE OF OFFICIAL SIGNING FOR APPLICANT ORGANIZATION ( <i>Item 14</i> ) NAME <b>Peter Boyle</b> TITLE <b>Director</b> TEL 33-4-72.73.86.84   FAX 33-4-72.73.85.64 E-MAIL <b>director@iarc.fr</b>	

12. Corrections to Page 1 Face Page

13. APPLICANT ORGANIZATION CERTIFICATION AND ACCEPTANCE: I certify that the statements herein are true, complete and accurate to the best of my knowledge, and accept the obligation to comply with Public Health Services terms and conditions if a grant is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties.	SIGNATURE OF OFFICIAL NAMED IN 11c. ( <i>In ink. "Per" signature not acceptable.</i> ) 	DATE <b>11/7/08</b>
--	--	------------------------

Principal Investigator/Program Director (Last, First, Middle): Cogliano, Vincent James

DETAILED BUDGET FOR NEXT BUDGET PERIOD – DIRECT COSTS ONLY		FROM 09/01/2008	THROUGH 08/31/2009	GRANT NUMBER 3U01CA033193-25W1			
PERSONNEL (Applicant organization only)		Months Devoted to Project			DOLLAR AMOUNT REQUESTED (omit cents)		
NAME	ROLE ON PROJECT	Cal. Mnth	Acad. Mnth	Sum. Mnth	SALARY REQUESTED	FRINGE BENEFITS	TOTALS
COGLIANO, V.J.	Principal Investigator	(b)(4), (b)(6)			0	0	0
EL-GHISSASSI, F.	Scientist				85,800	28,600	114,400
P2 IARC Scientist *	Scientist	12			91,950	30,650	122,600
P2 IARC Scientist *	Scientist	12			85,650	28,550	114,200
P1 IARC Scientist *	Scientist	12			62,900	21,000	83,900
EGRAZ, S.	Archivist	(b)(4), (b)(6)			73,350	24,450	97,800
<b>SUBTOTALS</b> →					<b>399,650</b>	<b>133,250</b>	<b>532,900</b>
CONSULTANT COSTS See page 3							26,548
EQUIPMENT (Itemize)							
SUPPLIES (Itemize by category)							
TRAVEL One trip of PI to USA for a scientific meeting and to consult with NCI program officials							2,150
PATIENT CARE COSTS		INPATIENT					
		OUTPATIENT					
ALTERATIONS AND RENOVATIONS (Itemize by category)							
OTHER EXPENSES (Itemize by category) See page 3							151,184
<b>SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD</b>							<b>\$ 712,782</b>
CONSORTIUM/CONTRACTUAL COSTS		DIRECT COSTS					
		FACILITIES AND ADMINISTRATIVE COSTS					
<b>TOTAL DIRECT COSTS FOR NEXT PROJECT PERIOD (Item 8a, Face Page)</b>							<b>\$ 712,782</b>

Principal Investigator/Program Director (Last, First, Middle): **Cogliano, Vincent James**

**BUDGET JUSTIFICATION**

GRANT NUMBER  
3U01CA033193-25W1

Provide a detailed budget justification for those line items and amounts that represent a significant change from that previously recommended. Use continuation pages if necessary.

**CONSULTANT :**

In accordance with the payment schedule on IARC's contract with Technical Resources International Inc, to remain within the limits of the recommended support for year 27 of the grant, and to ensure the funding for two working groups and printing of two volumes, only the funds scheduled to be paid to TRI Inc. during the budget period for year 27 are included here.

No honorarium will be paid to experts for the preparation of draft monographs and the editing work will be funded by other sources.

**OTHER :**

- Working groups (\$60,000 X 2)	\$120,000
- Printing of Monographs (\$15,000 X 2)	\$ 30,000
- Books, journals and reproduction costs	\$ 1,184
	-----
	\$151,184

**\* PERSONNEL :**

The 2 P2 and the P1 IARC Scientist posts are currently occupied by Dr Tallaa L., Dr Bouvard V. and Dr Guha N.

**CURRENT BUDGET PERIOD**

FROM  
09/01/2007

THROUGH  
08/31/2008

Explain any estimated unobligated balance (including prior year carryover) that is greater than 25% of the current year's total budget.

	Total estimated expenditure -----	Estimated unobligated balance -----
DIRECT COSTS	\$693,274	\$0
INDIRECT COSTS	\$ 90,126	\$0
-----		
TOTAL COSTS	\$783,400	\$0

Principal Investigator/Program Director (Last, First, Middle): Cogliano, Vincent James

Other Active Support

(b)(4), (b)(6)

01/01/08-12/31/08  
\$84,000

(b)  
(4),  
%

The IARC Monographs 2008

No overlap with the NCI cooperative agreement. Funds used to support the 3<sup>rd</sup> Monographs meeting each year and scientific or advisory meetings relevant to the Monographs Programme.

NIEHS

\$100,000

Funds used to support document-production activities and temporary staffing of the Monographs programme.

Principal Investigator/Program Director (Last, First, Middle): Cogliano, Vincent James

<b>PROGRESS REPORT SUMMARY</b>	GRANT NUMBER 3U01CA033193-25W1	
	PERIOD COVERED BY THIS REPORT	
PRINCIPAL INVESTIGATOR OR PROGRAM DIRECTOR Cogliano, Vincent James	FROM 09/01/2007	THROUGH 08/31/2008
APPLICANT ORGANIZATION International Agency for Research on Cancer		
TITLE OF PROJECT (Repeat title shown in Item 1 on first page) Evaluation of Carcinogenic Risks to Humans		
A. Human Subjects (Complete Item 6 on the Face Page)		
Involvement of Human Subjects	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
B. Vertebrate Animals (Complete Item 7 on the Face Page)		
Use of Vertebrate Animals	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
C. Select Agent Research	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
D. Multiple PI Leadership Plan	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change

SEE PHS 2590 INSTRUCTIONS.

**WOMEN AND MINORITY INCLUSION:** See PHS 398 Instructions. Use Inclusion Enrollment Report Format Page and, if necessary, Targeted/Planned Enrollment Format Page.

a. Specific Aims. [unchanged from original application] The aim of the IARC Monographs is to critically review and evaluate the published scientific evidence on carcinogenic hazards to which humans are exposed. These include chemicals, complex mixtures, occupational exposures, physical and biological agents, and lifestyle factors. International, interdisciplinary Working Groups write the critical reviews and develop the evaluations.

b. Studies and Results. During the past reporting year, IARC convened Working Groups to develop two new volumes of IARC Monographs. Topics for these volumes had been recommended as high priorities by IARC Monographs Advisory Groups in February 2003 and September 2006.

Volume 98: Shift-work, painting, and fire-fighting. Nearly 20% of the working population in North America and Europe engages in shift-work, which is most prevalent in the health-care, industrial, manufacturing, mining, transport, communication, leisure, and hospitality sectors. Among the many different patterns of shift-work, those that include night-work are most disruptive for the circadian clock. Epidemiological studies in a limited range of occupations have found that night-work can increase the risk of cancer, and experimental studies have shown that the disrupting the circadian system can induce tumour development.

Another occupational exposure, painting, can result in exposure to many chemical pigments, solvents, and additives. Painters can also be exposed to other workplace hazards, such as asbestos and crystalline silica. Epidemiological studies of painters have shown consistent increases in lung cancer and bladder cancer. In addition, there is some evidence of childhood leukaemia associated with maternal exposure to paint.

A third occupational group, fire-fighters, are exposed to numerous toxic chemicals, including many known or suspected carcinogens. These intermittent exposures can be intense, and short-term exposure levels can be high for respirable particulate matter and for some carcinogens, notably benzene, benzo[a]pyrene, 1,3-butadiene, and formaldehyde. Epidemiological studies suggest some potential for an increased cancer risk,

Principal Investigator/Program Director (Last, First, Middle): Cogliano, Vincent James

but consistent patterns are difficult to discern due to the large variations in exposure across different fires and different groups of fire-fighters.

A Working Group of 24 scientists from 10 countries met in October 2007 to critically review the pertinent scientific literature and develop the following evaluations.

Shift-work that involves circadian disruption	<i>Probably carcinogenic</i> (Group 2A) *
Occupational exposure as a painter	<i>Carcinogenic to humans</i> (Group 1)
Occupational exposure as a fire-fighter	<i>Possibly carcinogenic</i> (Group 2B) *

\* New agent never before reviewed by the *Monographs*

### Volume 99: Some industrial and cosmetic dyes and related occupations.

Several industrial dyes that are aromatic amines have long been known to cause bladder cancer in humans, and many others are suspected of being carcinogenic. This volume considers a large class of aromatic amines used as dyes in order that mechanistic similarities within the class might be considered in the overall evaluations.

This volume also reviews the occupational exposures of hairdressers and barbers, which already was an occupation suspected of causing cancer in humans. At the same time, the studies on personal use of hair colorants were reviewed. This is a widespread exposure not only in the United States, but also worldwide.

A Working Group of 17 scientists from 7 countries met in February 2008 to critically review the pertinent scientific literature and develop the following evaluations.

4-Aminobiphenyl	<i>Carcinogenic to humans</i> (Group 1)
Benzidine	<i>Carcinogenic to humans</i> (Group 1)
Dyes metabolized to benzidine	<i>Carcinogenic to humans</i> (Group 1) **
4,4'-Methylenebis(chloroaniline) (MOCA)	<i>Carcinogenic to humans</i> (Group 1) **
2-Naphthylamine	<i>Carcinogenic to humans</i> (Group 1)
<i>ortho</i> -Toluidine	<i>Carcinogenic to humans</i> (Group 1) **
Auramine production	<i>Carcinogenic to humans</i> (Group 1)
Magenta production	<i>Carcinogenic to humans</i> (Group 1)
4-Chloro- <i>ortho</i> -toluidine	<i>Probably carcinogenic</i> (Group 2A)
Auramine, technical grade	<i>Possibly carcinogenic</i> (Group 2B)
Magenta	<i>Possibly carcinogenic</i> (Group 2B)
Michler's base	<i>Possibly carcinogenic</i> (Group 2B) *
Michler's ketone	<i>Possibly carcinogenic</i> (Group 2B) *
Occupational exposure of hairdressers and barbers	<i>Probably carcinogenic</i> (Group 2A)
Personal use of hair colorants	<i>Not classifiable</i> (Group 3)

\* New agent never before reviewed by the *Monographs*

\*\* New evaluation that is higher than the prior evaluation of this agent

In addition, the *Monographs* programme convened an Advisory Group in June 2008 to recommend agents that warrant high priority for consideration in future *Monographs*. This Advisory Group also reviewed the plans and progress in the development of Volume 100, which will be a review of the human carcinogens identified to date. Six meetings have been scheduled between Oct 2008 and Oct 2009 to prepare *Monographs* for the approximately 100 agents that have been classified in Group 1 by the *Monographs* programme.

**The Advisory Group recommended that the following agents be evaluated with high priority during 2010-2014:**

Acetaldehyde  
Acrylamide and furan  
Air pollution \*  
Bitumen  
Carbon-based nanomaterials \*  
Crystalline fibres other than asbestos \*  
Growth hormone \*  
Iron and iron oxides \*  
Motor vehicle engine exhausts  
Nucleoside-analogue antiviral drugs  
PFOA and other perfluorinated compounds \*  
Polyomaviruses (SV40, BK, JC, Merkel cell virus) \*  
Radiofrequency electromagnetic fields (includes mobile telephones) \*  
Sedentary work \*  
Statins \*  
Stress \*  
Testosterone and other androgenic steroids  
Ultrafine particles \*  
Welding  
Agents recently tested in experimental animals \*

Most of these agents (marked with an asterisk) have never before been reviewed by the *Monographs* programme. This indicates a high level of interest in the continued work of the *Monographs* programme.

**The Advisory Group also recommended that the following agents be evaluated with medium priority during 2010-2014:**

Artificial sweeteners (acesulfame potassium, aspartame, sucralose)  
Atrazine  
Dyes metabolized to 3,3'-dimethylbenzidine  
Dyes metabolized to 3,3'-dimethoxybenzidine  
Herbs and other alternative medicines  
Metalworking fluids and lubricants  
Methotrexate and anti-TNF antibody therapy  
MTBE and other fuel additives  
N-Nitroso compounds with widespread exposure (e.g., N-nitroso(di-n-propyl)amine)  
PBBs (polybrominated biphenyls)  
PBDEs (polybrominated diphenyl ethers)  
PCBs (polychlorinated biphenyls)  
Primidone  
Salicylazosulfapyridine  
Some phthalates (DEHP, DINP)  
Styrene  
Ultraviolet radiation, broad-spectrum UV radiation, sunlamps and sunbeds

[NCI funding was not used to support this Advisory Group meeting.]

**c. Significance.** More than 400 carcinogenic or potentially carcinogenic agents have been identified among the approximately 900 agents evaluated in the first 99 volumes of *IARC Monographs*. National and international health agencies use the *IARC Monographs* as a source of information on potential carcinogens

Principal Investigator/Program Director (Last, First, Middle): Cogliano, Vincent James

and as scientific support for their actions to reduce exposure to potential carcinogens. The *IARC Monographs* also are a resource to the scientific community for information on agents suspected of causing cancer.

**d. Plans.** During the next budget period from September 2008 through August 2009, IARC will convene four more expert Working Groups to evaluate information on high-priority carcinogenic agents. [NCI funding will support two of these Working Groups.]

Volume 100, meeting A: Pharmaceuticals (23 agents) (14-21 Oct 2008).  
Volume 100, meeting B: Biological agents (11 agents) (24 Feb-3 Mar 2009).  
Volume 100, meeting C: Metals, particles and fibres (14 agents) (17-24 Mar 2009).  
Volume 100, meeting D: Radiation (14 agents) (2-9 June 2009).

**Information on these meetings is available on the *Monographs* programme website, <http://monographs.iarc.fr/>, at Future Meetings. Included on the website is a Call for Data, a Call for Experts (now closed), and information on how to Request Observer Status.**

#### **e. Publications**

Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Cogliano V., on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of some aromatic amines, organic dyes, and related exposures. *Lancet Oncology* 2008; 9: 322-323

Cogliano VJ (2007) The IARC Monographs: a resource for precaution and prevention. *Occupational and Environmental Medicine* 64(9): 572 (invited commentary).

Cogliano VJ, Baan RA, Straif K, Grosse Y, Secretan B, El Ghissassi F (2008) Use of mechanistic data in IARC evaluations. *Environmental and Molecular Mutagenesis* 49(2): 100-109.

Cogliano VJ, Baan RA, Straif K, Grosse Y, Secretan MB, El Ghissassi F. The IARC Monographs' Approach to Characterizing Evidence. In: Wiedemann PM & Schütz H. eds. *The role of evidence in risk characterization*. Weinheim, Wiley-VCH, 2008, pp. 101-109

Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Cogliano V, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group (2007). Carcinogenicity of 1,3-butadiene, ethylene oxide, vinyl chloride, vinyl fluoride, and vinyl bromide. *Lancet Oncol.*, 8, 679-680

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 89, Smokeless tobacco and some tobacco-specific N-nitrosamines nitrosamines. Geneva, WHO Press (2007)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 90, Human papilloma-viruses. Geneva, WHO Press (2007)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 91, Combined estrogen-progestogen contraceptives and combines estrogen-progestogen menopausal therapy. Geneva, WHO Press (2007)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 92, Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. Geneva, WHO Press (in prep.)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 93, Carbon black, titanium, and non-asbestiform talc. Geneva, WHO Press (in prep.)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 94, Ingested nitrates and nitrites and cyanobacterial peptide toxins. Geneva, WHO Press (in prep.)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 95, Indoor air pollution from household cooking and heating: solid-fuel use and high-temperature frying. Geneva, WHO Press (in prep.)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 96, Alcoholic beverages and ethyl carbamate. Geneva, WHO Press (in prep.)

Principal Investigator/Program Director (Last, First, Middle): Cogliano, Vincent James

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 97, 1,3-Butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl chloride and vinyl bromide). Geneva, WHO Press (in press)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 98, Fire-fighting, painting and shift-work. Geneva, WHO Press (in press)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 99, Some aromatic amines, organic dyes, and related exposures. Geneva, WHO Press (in press)

Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Benbrahim-Tallaa L, Cogliano V, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group (2007). Carcinogenicity of shift-work, painting, and fire-fighting. *Lancet Oncol.*, 8, 1065-1066.

**All *Lancet Oncology* summaries (published every 4 months since August 2004) are open-access on the Internet for subscribers and non-subscribers alike. In addition, Volumes 83-91 of the *IARC Monographs* are now available in full for free on the *Monographs* programme website (<http://monographs.iarc.fr/>) and other volumes are being added.**

f. **Project-Generated Resources.** None.

Principal Investigator/Program Director (Last, first, middle): Cogliano, Vincent James

GRANT NUMBER  
3U01CA033193-25W1

### CHECKLIST

#### 1. PROGRAM INCOME (See instructions.)

All applications must indicate whether program income is anticipated during the period(s) for which grant support is requested. If program income is anticipated, use the format below to reflect the amount and source(s).

Budget Period	Anticipated Amount	Source(s)

#### 2. ASSURANCES/CERTIFICATIONS (See instructions.)

In signing the application Face Page, the authorized organizational representative agrees to comply with the following policies, assurances and/or certifications when applicable. Descriptions of individual assurances/certifications are provided in Part III of the PHS 398. If unable to certify compliance, where applicable, provide an explanation and place it after this page.

• Human Subjects Research • Research Using Human Embryonic Stem Cells • Research on Transplantation of Human Fetal Tissue • Women and Minority Inclusion Policy • Inclusion of Children Policy • Vertebrate Animals

• Debarment and Suspension • Drug- Free Workplace (applicable to new [Type 1] or revised/resubmission [Type 1] applications only) • Lobbying • Non-Delinquency on Federal Debt • Research Misconduct • Civil Rights (Form HHS 441 or HHS 690) • Handicapped Individuals (Form HHS 641 or HHS 690) • Sex Discrimination (Form HHS 639-A or HHS 690) • Age Discrimination (Form HHS 680 or HHS 690) • Recombinant DNA Research, Including Human Gene Transfer Research • Financial Conflict of Interest (except Phase I SBIR/STTR) • Prohibited Research • Select Agent Research • PI Assurance • STTR ONLY: Certification of Research Institution Participation.

#### 3. FACILITIES AND ADMINISTRATIVE (F&A) COSTS

Indicate the applicant organization's most recent F&A cost rate established with the appropriate DHHS Regional Office, or, in the case of for-profit organizations, the rate established with the appropriate PHS Agency Cost Advisory Office.

F&A costs will **not** be paid on construction grants, grants to Federal organizations, grants to individuals, and conference grants. Follow any additional instructions provided for Research Career Awards, Institutional National Research Service Awards, Small Business Innovation Research/Small Business Technology Transfer Grants, foreign grants, and specialized grant applications.

DHHS Agreement dated: \_\_\_\_\_  No Facilities and Administrative Costs Requested.

No DHHS Agreement, but rate established with J.W. Berry, Accountant, DHHS Date 10/18/1983

#### CALCULATION\*

Entire proposed budget period: Amount of base \$ 712,782 x Rate applied 13.00 % = F&A costs \$ 92,662

Add to total direct costs from Form Page 2 and enter new total on Face Page, Item 8b.

\*Check appropriate box(es):

Salary and wages base  Modified total direct cost base  Other base (Explain)

Off-site, other special rate, or more than one rate involved (Explain)

Explanation (Attach separate sheet, if necessary.):

Rate applied to total direct costs

Principal Investigator/Program Director (Last, First, Middle): **Cogliano, Vincent James**

**KEY PERSONNEL REPORT**

GRANT NUMBER  
3U01CA033193-25W1

Place this form at the end of the signed original copy of the application. Do not duplicate.

**All Key Personnel for the Current Budget Period (do not include Other Significant Contributors)**

Name	Degree(s)	SSN (last 4 digits)	Role on Project (e.g. PI, Res. Assoc.)	Date of Birth (MM/DD/YY)	Months Devoted to Project		
					Cal	Acad	Sum
VJ Cogliano	PhD	(b)(6)	PI	(b)(6)	(b)(4), (b)(6)		
V Bouvard	PhD	N/A	Scientist				
R Baan	PhD	N/A	Scientist				
F El Ghissassi	PhD	N/A	Scientist				
Y Grosse	PhD	N/A	Scientist				
N Guha	PhD	(b)(6)	Scientist				
B Secretan	PhD	N/A	Scientist				
K Straif	MD, PhD	N/A	Scientist				
L Tallaa	PhD	N/A	Scientist				



**INTERNATIONAL AGENCY FOR RESEARCH ON CANCER  
CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER**

150 cours Albert Thomas, 69372 Lyon cedex 08, France <http://www.iarc.fr>

Carcinogen Identification and  
Evaluation Group  
Tel.: +33 4 72 73 85 07  
Fax: +33 4 72 73 83 19  
E-mail: [cie@iarc.fr](mailto:cie@iarc.fr)

Division of Extramural Activities  
Support, OER  
National Institutes of Health  
6705 Rockledge Drive, Room 2207,  
MSC 7987  
Bethesda, MD 20817  
USA

Special courier: tel. 1-301-594.6584

Ref.: CI/43/3

26 June 2008

Dear Sirs,

I enclose an original and one copy of the Grant Progress Report 3U01CA033193-25W1 for the budget period from 1 September 2007 to 31 August 2008, including the budget request of the next period from 1 September 2008 to 31 August 2009.

I trust the enclosed report is satisfactory and look forward to our continued collaboration.

Yours sincerely,

Vincent James Cogliano  
Head, Carcinogen Identification and Evaluation

ENCL: As mentioned